<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi>, an inhibitor of the epidermal growth factor receptor (EGFR), induces differentiation, cell-cycle arrest, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of EGFR-negative myeloblasts of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), as well as in EGFR-negative cell lines representing these diseases (P39, KG-1, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> 60) </plain></SENT>
<SENT sid="1" pm="."><plain>This off-target effect can be explained by inhibitory effects on JAK2 </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> induction coupled to <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane permeabilization occurred independently from phenotypic differentiation </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-sensitive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells, <z:chebi fb="0" ids="114785">erlotinib</z:chebi> caused a rapid (within less than 1 hour) nucleocytoplasmic translocation of nucleophosmin-1 (NPM-1) and p14(ARF) </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath>-insensitive myeloblasts failed to manifest this translocation yet became sensitive to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction by <z:chebi fb="0" ids="114785">erlotinib</z:chebi> when NPM-1 was depleted by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, <z:chebi fb="0" ids="114785">erlotinib</z:chebi> reduced the growth of xenografted human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells in vivo </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi> also killed CD34(+) bone marrow blasts from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients while sparing <z:mpath ids='MPATH_458'>normal</z:mpath> CD34(+) progenitors </plain></SENT>
<SENT sid="7" pm="."><plain>This ex vivo therapeutic effect was once more associated with the nucleocytoplasmic translocation of NPM-1 and p14(ARF) </plain></SENT>
<SENT sid="8" pm="."><plain>One patient afflicted with both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> manifested hematologic improvement in response to <z:chebi fb="0" ids="114785">erlotinib</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, we here provide novel evidence in vitro, ex vivo, and in vivo for the potential therapeutic efficacy of <z:chebi fb="0" ids="114785">erlotinib</z:chebi> in the treatment of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>